Skip to main content

Advertisement

SpringerLink
Log in

Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Summary

Recent evidence suggests that intramedullary apoptosis in MDS contributes to the ineffective erythropoiesis with anemia. Although conflicting data exist about the level of apoptosis in bone marrow erythroblasts, apoptosis might play an important role in MDS but cannot explain in all cases the observed refractory anemia. To further unravel the precise mechanisms, more insight into the signaling pathway of apoptosis in MDS is warranted. In addition, the role of ineffective terminal differentiation of the erythropoiesis related to the apoptotic signaling pathways may further help understanding the pathogenesis of MDS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenberg Pet al. International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood 1997;89: 2079–2088.

    Article  CAS  PubMed  Google Scholar 

  2. Backs B, Broeders L, Löwenberg B. Kit ligand in vitro erythropoiesis in myelodysplastic syndrome.Blood 1992;80: 1213–1217.

    Article  Google Scholar 

  3. Brada Set al. The supportive effects of erythropoietin and mast cell growth factor on CD34+/CD36− sorted bone marrow cells of myelodysplasia patients.Blood 1996;87: 505–510.

    Article  Google Scholar 

  4. Brada SJL, Wolf JThM de, Hendriks DW, Smit JW, Vellenga E. CD34+/CD36 cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation.Leukemia 1998;12: 882–886.

    Article  CAS  PubMed  Google Scholar 

  5. Brada SJLet al. Characterization of the erythropoiesis in myelodysplasia by means of ferrokinetic studies, in vitro erythroid colony formation and soluble transferrin receptor.Leukemia 1998;12: 340–345.

    Article  CAS  PubMed  Google Scholar 

  6. Thornberry NA, Lazebnik Y. Caspases: enemies within.Science 1998;281: 1312–1316.

    Article  CAS  PubMed  Google Scholar 

  7. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation.Science 1998;281: 1305–1308.

    Article  CAS  PubMed  Google Scholar 

  8. Stahnke K, Hecker S, Kohne E, Debatin KM. CD95 (APO1/Fas)-mediated apoptosis in cytokine activated hematopoietic cells.Exp Hematol 1998;26: 844–850.

    CAS  PubMed  Google Scholar 

  9. Sidoti-de Fraisse C, Rincheval V, Risler Y, Mignotte B, Vayssière. TNF-α activates at least two apoptotic signaling cascades.Oncogene 1998;17: 1639–1651.

    Article  CAS  PubMed  Google Scholar 

  10. Yamashita Ket al. Caspase mediate tumor necrosis factor-α-induced neutrophil apoptosis and downregulation of reactive oxygen production.Blood 1999;93: 674–685.

    Article  CAS  PubMed  Google Scholar 

  11. Panzenböck B, Bartunek P, Mapara MY, Zenke M. Growth and differentiation of human stem cell factor/ erythropoietin-dependent erythroid progenitor cells in vitro.Blood 1998;92: 3658–3668.

    Article  PubMed  Google Scholar 

  12. De Maria Ret al. Apoptotic role of Fas/Fas-L ligand system in the regulation of erythropoiesis.Blood 1999;93: 796–803.

    Article  PubMed  Google Scholar 

  13. Munker R, Midis G, Owen-Schaub L, Andreff M. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes.Leukemia 1996;10: 1531–1533.

    CAS  PubMed  Google Scholar 

  14. Gersuk Get al. A role for tumour necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome.Br J Haematol 1998;103: 176–188.

    Article  CAS  PubMed  Google Scholar 

  15. Kitagawa Met al. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia.Leukemia 1998;12: 486–492.

    Article  CAS  PubMed  Google Scholar 

  16. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A. Is apoptosis a massive process in myelodysplastic syndromes?Br J Haematol 1996;95: 368–371.

    Article  CAS  PubMed  Google Scholar 

  17. Hanspal M, Hanspal JS. The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact.Blood 1994;84: 3494–3504.

    Article  CAS  PubMed  Google Scholar 

  18. Hanspal M, Smockova Y, Yong Q. Molecular identification and functional characterization of a novel protein that mediates the attachment of erythroblasts to macrophages.Blood 1998;92: 2940–2950.

    Article  CAS  PubMed  Google Scholar 

  19. Mundle SDet al. Evidence for involvement of tumor necrosis factor-α in apoptotic death of bone marrow cells in myelodysplastic syndromes.Am J Hematol 1999;60: 36–47.

    Article  CAS  PubMed  Google Scholar 

  20. Green DR, Reed JC. Mitochondria and apoptosis.Science 1998;281: 1309–1313.

    Article  CAS  PubMed  Google Scholar 

  21. Kroemer G, Zamzani N, Susin SA. Mitochondrial control of apoptosis.Immunol Today 1997;18: 44–51.

    Article  CAS  PubMed  Google Scholar 

  22. Petit PXet al. Implication of mitochondria in apoptosis.Mol Cell Biochem 1997;174: 185–188.

    Article  CAS  PubMed  Google Scholar 

  23. Bradham CAet al. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release.Mol Cell Biol 1998;18: 6353–6364.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Petit PXet al. Disruption of the outer mitochondrial membrane as a result of large amplitude swelling: the impact of irreversible permeability transition.FEBS Lett 1998;426: 111–116.

    Article  CAS  PubMed  Google Scholar 

  25. Hengarter MO. Death cycle and Swiss army knives.Nature 1998;391: 441–442.

    Article  Google Scholar 

  26. Susin SAet al. Molecular characterization of mitochondrial apoptosis-inducing factor.Nature 1999;397: 441–445.

    Article  CAS  PubMed  Google Scholar 

  27. Bossy-Wetzel E, Newmeyer DD, Green DR. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization.EMBO 1998;17: 37–49.

    Article  CAS  Google Scholar 

  28. Kuwana Tet al. Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c.J Biol Chem 1998;273: 16589–16594.

    Article  CAS  PubMed  Google Scholar 

  29. Steemans Met al. A caspase-activated factor (CAF) induces mitochondrial membrane depolarization and cytochrome c release by a nonproteolytic mechanism.J Exp Med 1998;188: 2193–2198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mashima Tet al. Actin cleavage by CPP-32/apopain during the development of apoptosis.Oncogene 1997;14: 1007–1012.

    Article  CAS  PubMed  Google Scholar 

  31. Carulli Get al. Actin polymerization in neutrophils from patients affected by myelodysplastic syndromes—a flow cytometric study.Leuk Res 1997;21: 513–518.

    Article  CAS  PubMed  Google Scholar 

  32. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the bcl-2 family and cell death.Blood 1996;88: 386–401.

    Article  CAS  PubMed  Google Scholar 

  33. Adams JM, Cory S. The bcl-2 protein family: arbiters of cell survival.Science 1998;281: 1322–1325.

    Article  CAS  PubMed  Google Scholar 

  34. Kharbanda Set al. Role for Bcl-XL as an inhibitor of cytosolic cytochrome c accumulation in DNA damage-induced apoptosis.Proc Natl Acad Sci USA 1997;94: 6939–6942.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Finucane D, Bossey-Wetzel E, Waterhouse NJ, Cotter TG, Green DR. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by bcl-xL.J Biol Chem 1999;274: 2225–2233.

    Article  CAS  PubMed  Google Scholar 

  36. Gregoli PA, Bondurant MC. the roles of bcl-XL and apopain in the control of erythropoiesis by erythropoietin.Blood 1997;90: 630–640.

    Article  CAS  PubMed  Google Scholar 

  37. Garland JM, Rudin C. Cytochrome c induces caspase-dependent apoptosis in intact hematopoietic cells and overrides apoptosis suppression mediated by bcl-2, growth factor signaling, MAP-kinase-kinase and malignant change.Blood 1998;92: 1235–1246.

    Article  CAS  PubMed  Google Scholar 

  38. Rossé Tet al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c.Nature 1998;391: 496–499.

    Article  PubMed  Google Scholar 

  39. Raza Aet al. Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo-and/or bromodeoxyuridine.Exp Hematol 1997;25: 530–535.

    CAS  PubMed  Google Scholar 

  40. Raza Aet al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis.Am J Hematol 1995;48: 143–154.

    Article  CAS  PubMed  Google Scholar 

  41. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes.Br J Haematol 1998;101: 220–230.

    Article  CAS  PubMed  Google Scholar 

  42. Irvine AE, Magil MK, Somerville LE, McMullin MF. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia.Exp Hematol 1998;26: 435–439.

    CAS  PubMed  Google Scholar 

  43. Mundle S, Shetty VT, Raza A. Is excessive spontaneous intramedullary apoptosis unique to myelodysplasia?Exp Hematol 1998;26: 1014–1015.

    CAS  PubMed  Google Scholar 

  44. Raza Aet al. A paradigm in myelodysplastic syndromes.Leukemia 1996;10: 1648–1652.

    CAS  PubMed  Google Scholar 

  45. Raza Aet al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.Blood 1995;86: 268–276.

    Article  CAS  PubMed  Google Scholar 

  46. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes; implications for disease natural history and treatment.Leuk Res 1998;22: 1123–1136.

    Article  CAS  PubMed  Google Scholar 

  47. van de Loosdrecht AA, Vellenga E. Ultrastructural characteristics of erythroblasts in myelodysplasia. Relation to FAB, IPPS, cytogenetics and transfusion dependency (in preparation).

  48. Bogdanović ADet al. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment.Leukemia 1997;11: 656–659.

    Article  PubMed  Google Scholar 

  49. Parker JEet al. Low-risk myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins.Br J Haematol 1998;105: 1075–1082.

    Article  Google Scholar 

  50. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.Blood 1996;88: 4275–4287.

    Article  CAS  PubMed  Google Scholar 

  51. Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression.Leuk Res 1998;22: 767–777.

    Article  CAS  PubMed  Google Scholar 

  52. Hellström-Lindberg E, Kanter-Lewensohn L, Öst Å. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin.Leuk Res 1997;21: 415–425.

    Article  PubMed  Google Scholar 

  53. Stasi R, Pagano A, Terzoli E, Amadori S. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.Br J Haematol 1999;105: 141–148.

    CAS  PubMed  Google Scholar 

  54. Molldrem JJet al. Antithymocyte globulin for patients with myelodysplastic syndrome.Br J Haematol 1997;99: 699–705.

    Article  CAS  PubMed  Google Scholar 

  55. List AFet al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.Blood 1997;90: 3364–3369.

    Article  CAS  PubMed  Google Scholar 

  56. Moroni Met al. ‘Tunnel’ evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient with amifostine.Br J Haematol 1999;104 424–425.

    Article  CAS  PubMed  Google Scholar 

  57. Demuynck Het al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.Bone Marrow Transplant 1996;17: 745–751.

    CAS  PubMed  Google Scholar 

  58. De Witte Tet al. Autologous bone marrow transplantation for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS.Blood 1997;90: 3853–3857.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Academisch Ziekenhuis Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands

    AA van de Loosdrecht & E Vellenga

Authors
  1. AA van de Loosdrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Vellenga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to AA van de Loosdrecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van de Loosdrecht, A., Vellenga, E. Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis. Med Oncol 17, 16–21 (2000). https://doi.org/10.1007/BF02826211

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02826211

Keywords

Search

Navigation